INTERVENTIONAL IMMUNO-ONCOLOGY
Location: United States, Missouri, Saint Louis
Total raised: $23.9M
Investors 7
| Date | Name | Website |
| - | Centennial... | centennial... |
| - | Cultivatio... | cultivatio... |
| - | iSelect Fu... | iselectfun... |
| - | Tech Coast... | techcoasta... |
| - | SeedFolio | seedfolio.... |
| - | Missouri T... | missourite... |
| - | Argonautic | argonautic... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 25.10.2022 | Grant | $2.5M | - |
| 06.04.2022 | - | $21.4M | - |
Mentions in press and media 23
| Date | Title | Description |
| 24.02.2026 | Immunophotonics Secures European Patent Protecting Use of Lead Asset in Combination with Checkpoint Inhibitors | Additional intellectual property protection reinforces the strategic value of IP-001 and supports ongoing clinical development efforts. SAINT LOUIS, MO, UNITED STATES, February 24, 2026 /EINPresswire.com/ -- Immunophotonics, Inc., a clinica... |
| 15.04.2025 | Jacqueline Hess Joins Immunophotonics Board of Directors | ST. LOUIS, MO, UNITED STATES, April 15, 2025 /EINPresswire.com/ -- Immunophotonics, Inc., a clinical-stage biotech company focused on immuno-oncology, is pleased to announce the appointment of Jacqueline Hess to its Board of Directors. With... |
| 13.09.2024 | Immunophotonics, CIRSE, and Next Research Announce Innovative Phase 2/3 Clinical Trial: INJECTABL-3 | ST. LOUIS, MO, UNITED STATES, September 13, 2024 /EINPresswire.com/ -- Immunophotonics, Inc., a clinical-stage biopharma company developing novel immune-stimulating drugs to augment routine tumor destruction techniques – such as tumor ablat... |
| 15.08.2024 | Immunophotonics Announces 1st Patient Dosed in a Randomized Phase 2 Study at the University of Louisville | SAINT LOUIS, MISSOURI, USA, August 15, 2024 /EINPresswire.com/ -- Immunophotonics, Inc., a clinical-stage biotech company focused on the discovery and development of novel immune-activating drugs, in collaboration with Dr. Robert CG Martin ... |
| 26.06.2024 | Envisioning a future where food is synonymous with health, fostering longevity, productivity, and societal well-being | If you missed Carter’s testimony at the Senate hearing, “Feeding a Healthier America: Current Efforts and Potential Opportunities for Food is Medicine,” the replay is available here. The hearing emphasized the importance of nutrition to red... |
| 27.02.2024 | AngioDynamics and Immunophotonics Announces Partnership to Explore the Power of Immunotherapy | LATHAM, NEW YORK, February 27, 2024 /EINPresswire.com/ -- AngioDynamics, Inc. (NASDAQ: ANGO), a global provider of medical devices, and Immunophotonics, Inc., a clinical-stage biopharma company focused on immuno-oncology, are pleased to ann... |
| 12.07.2023 | Immunophotonics Announces 1st Patient Dosed in Multinational Clinical trial in Germany | ST. LOUIS, MISSOURI, July 12, 2023/EINPresswire.com/ -- Immunophotonics, Inc., a clinical-stage biotech company focused on the discovery and development of novel immune-activating drugs, has announced the recruitment and the dosing of its f... |
| 31.05.2023 | Immunophotonics Announces 1st Patient Dosed in Multinational Clinical trial in the United Kingdom | SAINT LOUIS, MISSOURI, AND BERN SWITZERLAND, May 31, 2023/EINPresswire.com/ -- Immunophotonics, Inc., a clinical-stage biotech company focused on the discovery and development of novel immune-activating drugs, has announced the recruitment ... |
| 16.05.2023 | Immunophotonics Receives Green Light from FDA to Open Investigational New Drug (IND) Study for IP-001 in the U.S. | ST. LOUIS, MISSOURI, USA, May 16, 2023/EINPresswire.com/ -- Immunophotonics, Inc., a clinical-stage biotech company focused on the discovery and development of novel innate immune stimulating drugs with antigen depot properties, has announc... |
| 24.01.2023 | Immunophotonics Announces 1st Patient Dosed in IP-IIO-622 Phase 1b/2a Clinical Trial in Advanced Solid Tumor Indications | SAINT LOUIS, MISSOURI, USA, January 24, 2023 /EINPresswire.com/ -- Immunophotonics, Inc., a clinical-stage biotech company focused on the discovery and development of novel immune-activating drugs, has announced the initiation of recruitmen... |
Show more